SPONSORED CONTENT
Trademark registration service includes:
- Trademark attorney managed
- Federal trademark search
- Apply online - fast & easy
- Electronic filing of application
- You are always kept informed
FUSALIN
Pharmaceutical preparations used to treat one or more of the following: infectious diseases, cancer, pain, inflammation, cardiovascular diseases, neurological diseases, psychiatric conditions, dermatological diseases, gastrointestinal diseases, musculoskeletal diseases, endocrine and metabolic diseases, ophthalmologic diseases, reproductive diseases, and respiratory conditions.
Logo Design and Free Alerts provided by Trademarks On Call, Inc.
Status Alert: On Friday, July 11, 2025, the status for the FUSALIN mark changed to NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER .
|
On Friday, July 11, 2025, a U.S federal trademark application was filed for FUSALIN by Newcastle Bioecience, LLC, 999 Vanderbilt Beach Road, Suite 200, Naples, FL. The USPTO has assigned the FUSALIN mark the serial number 99280271. The FUSALIN mark has been filed in the category Pharmaceutical Products. The owner of the FUSALIN mark is listed as Newcastle Bioecience, LLC, 999 Vanderbilt Beach Road, Suite 200, Naples, FL. The correspondent for the FUSALIN mark is Joseph I. Hirsch Law Office of Joseph I. Hirsch of 4149 Georgia Avenue, Palo Alto, CA 94306-3813, United States. If you have licensing, usage or other questions concerning the FUSALIN mark, please contact the owner through the listed correspondent. The description provided for the FUSALIN mark is Pharmaceutical preparations used to treat one or more of the following: infectious diseases, cancer, pain, inflammation, cardiovascular diseases, neurological diseases, psychiatric conditions, dermatological diseases, gastrointestinal diseases, musculoskeletal diseases, endocrine and metabolic diseases, ophthalmologic diseases, reproductive diseases, and respiratory conditions. |
|
| Word Mark: | FUSALIN |
| Status: | NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER |
| Status Date: | 07/11/2025 |
| Serial Number: | 99280271 |
| Filing Date: | 07/11/2025 |
| Registration Number: | Not Available |
| Registration Date: | Not Available |
| Goods and Services: | Pharmaceutical preparations used to treat one or more of the following: infectious diseases, cancer, pain, inflammation, cardiovascular diseases, neurological diseases, psychiatric conditions, dermatological diseases, gastrointestinal diseases, musculoskeletal diseases, endocrine and metabolic diseases, ophthalmologic diseases, reproductive diseases, and respiratory conditions |
| Type Of Mark: | Trademark |
| Register Type: | Principal |
| Published For Opposition Date: | Not Available |
| Current Owner: | Newcastle Bioecience, LLC 999 Vanderbilt Beach Road, Suite 200 Naples, FL 34108 UNITED STATES |
| Mark Description: | Not Available |
| Mark Drawing Type: | Not Available |
| Design Search: | Not Available |
| Disclaimer: | Not Available |
| Correspondent: | Joseph I. Hirsch Law Office of Joseph I. Hirsch 4149 Georgia Avenue Palo Alto, CA 94306-3813 United States |
Class Information
| International Class(es): | 005 |
| US Class(es): | 005, 006, 018, 044, 046, 051, 052 |
| Primary Class: | Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| Class(es) Status: | Active |
| First Use Anywhere: | Not Available |
| First Use In Commerce: | Not Available |
| Retrieve Trademark Documents |
U.S. Trademark Registration
Services provided by law firm Classic Counsel, P.C.†
Trademark Watch
SPONSORED CONTENT
Trademark watch service includes:
- Watch for conflicting trademarks
- Full-time monitoring
- Reports emailed to you monthly
- Monitor how your trademark is being used
Services provided by law firm Classic Counsel, P.C.†
Services
Services provided by Trademarks On Call, Inc.